ATAI Life Sciences NV (9VC) — Long-term Investment Intensity
ATAI Life Sciences NV (9VC) has a Long-term Investment Intensity of 36.8% as of September 2025. Long-term investments of €88.36 Million represent 36.8% of total assets of €239.82 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check how high is ATAI Life Sciences NV's earnings quality to evaluate the quality of earnings relative to operating cash generation.
LT Investment Intensity
Long-term Investments
Total Assets
Country
ATAI Life Sciences NV Long-term Investment Intensity (2019–2024)
This chart shows how ATAI Life Sciences NV's Long-term Investment Intensity has evolved across 6 annual periods from 2019 to 2024. As of September 2025, the intensity stands at 36.8%, reflecting long-term investments of €88.36 Million against total assets of €239.82 Million EUR. Explore ATAI Life Sciences NV debt service capacity to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for ATAI Life Sciences NV (2019–2024)
The table below presents the year-by-year Long-term Investment Intensity for ATAI Life Sciences NV from 2019 to 2024, covering 6 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see 9VC stock market capitalisation.
| Year | LT Investment Intensity | LT Investments (EUR) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 44.5% | €70.97 Million | €159.39 Million | ▲ +13.3 pp |
| 2023 | 31.2% | €91.66 Million | €293.48 Million | ▲ +29.0 pp |
| 2022 | 2.2% | €6.75 Million | €305.44 Million | ▼ -4.5 pp |
| 2021 | 6.7% | €27.76 Million | €414.17 Million | ▼ -0.5 pp |
| 2020 | 7.2% | €8.04 Million | €111.55 Million | ▼ -29.7 pp |
| 2019 | 36.9% | €22.95 Million | €62.12 Million | — |